Chugai Nets 40%-Plus Profit Rise, but Keeps 3-Year EPS Target; President Nixes Avastin Biosame

Chugai President & CEO Tatsuro Kosaka Chugai Pharmaceutical saw its profits surge over 40% in January-June, buoyed by new products such as Hemlibra (emicizumab) and Tecentriq (atezolizumab), but President and CEO Tatsuro Kosaka says the company will keep its conservative...read more